Article info
Rheumatoid arthritis
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
- Correspondence to Dr Xiaofeng Zeng; zengxfpumc{at}163.com; xiaofeng.zeng{at}cstar.org.cn
Citation
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Publication history
- Received July 8, 2024
- Accepted November 4, 2024
- First published November 27, 2024.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.